Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | MGTA-145 with plerixafor for the mobilization and collection of HSCs

John DiPersio • 3 Sep 2020
EBMT 2020
General MGTA-145 Plerixafor

John DiPersio, MD, PhD, Washington University, St. Louis, MO, discusses the use of MGTA-145, a novel, rapid mobilizing agent also known as truncated GRO-beta along with plerixafor for the mobilization and collection of hematopoietic stem cells (HSCs). In primate models, this combination resulted in the rapid mobilization of stem cells sufficient for autologous stem cell transplant and therefore could eliminate the use of granulocyte-colony stimulating factor (G-CSF). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from John DiPersio

4:02
Identifying the optimal toxic payloads for antibody-based SCT conditioning using SAv-drug conjugates
John DiPersio • 21 Feb 2023
5:08
LBA: CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio • 21 Feb 2023
4:13
ALL highlights: tisa-cel reinfusion in B-ALL & targeting CD5 and CD7 with CAR-Ts in T-ALL
John DiPersio • 21 Feb 2023
4:19
Advantages & concerns associated with the use of ADC-based conditioning in SCT recipients
John DiPersio • 21 Feb 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals